Ontario Institute for Cancer Research (oicr)

Propellon Therapeutics Inc.

University of Toronto

Ontario Institute for Cancer Research

David Uehling

Methvin Benjamin Isaac

Ahmed Mamai

Rima Al-Awar

Gennady Poda

Pandiaraju Subramanian

Brian Wilson

Babu Joseph

Yong Liu

Michael Prakesch

Carlos Armando Zepeda-Velazquez

Anh My Chau

Iain Watson

Sean Harrington

Mark Lautens

Andrew Burns

Jacob Pyche

Peter Roy

Rachel Ross

Genna M Luciani

Daniel Kulke

Julia Kathleen Stille

Justin-Alexander Morin

Julia Katheleen Stille

The present application is directed to compounds of Formula I:

Substituted carboxamides as inhibitors of WDR5 protein-protein binding

The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction

The present application relates to the treatment of nematode infections. For example, the application relates to the use of compounds of Formula I and/or II as defined herein for treatment of a nematode infection or a disease, disorder or condition arising from a nematode infection: 

Compounds and methods for treating nematode infections

The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners. 

The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer. 

Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof

The present application is directed to compounds of Formula I: compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

Growing community of inventors

Toronto, Canada

David Uehling